Table 2 Correlation between demographic and clinical factors and superior sulcus deepening
From: Periorbital changes associated with prostaglandin analogs in Korean patients
Superior sulcus deepening | p-value | ||
|---|---|---|---|
Yes (n = 14) | No (n = 44) | ||
Age (years) | 69.57 ± 8.97 | 56.95 ± 16.88 | 0.007* |
Gender (male: female) | 7:7 | 32:12 | 0.189† |
Duration of administration (months) | 49.50 ± 39.61 | 19.52 ± 24.46 | 0.002* |
Pre-treatment IOP (mmHg) | 17.57 ± 3.52 | 19.68 ± 7.39 | 0.512* |
IOP lowering effect (%) | 18.79 ± 16.14 | 27.98 ± 17.16 | 0.134* |
Visual field index | 73.86 ± 25.64 | 83.57 ± 21.76 | 0.085* |
History of cataract surgery (%) | 50.00 | 22.73 | 0.056† |
Type of glaucoma (%) | |||
NTG: POAG: Others | 9(64):4(29):1(7) | 29(66):5(11):10(23) | 0.228† |
Type of prostaglandin analogs (%) | |||
Latanoprost: Bimatoprost: Travoprost | 12(86):1(7):1(7) | 38(86):3(7):3(7) | 0.999† |
Combination of other eyedrops (%) | 42.86 | 38.64 | 0.508† |